Literature DB >> 7494564

Blood pressure and end-stage renal disease in men.

M J Klag1, P K Whelton, B L Randall, J D Neaton, F L Brancati, C E Ford, N B Shulman, J Stamler.   

Abstract

BACKGROUND: End-stage renal disease in the United States creates a large burden for both individuals and society as a whole. Efforts to prevent the condition require an understanding of modifiable risk factors.
METHODS: We assessed the development of end-stage renal disease through 1990 in 332,544 men, 35 to 57 years of age, who were screened between 1973 and 1975 for entry into the Multiple Risk Factor Intervention Trial (MRFIT). We used data from the national registry for treated end-stage renal disease of the Health Care Financing Administration and from records on death from renal disease from the National Death Index and the Social Security Administration.
RESULTS: During an average of 16 years of follow-up, 814 subjects either died of end-stage renal disease or were treated for that condition (15.6 cases per 100,000 person-years of observation). A strong, graded relation between both systolic and diastolic blood pressure and end-stage renal disease was identified, independent of associations between the disease and age, race, income, use of medication for diabetes mellitus, history of myocardial infarction, serum cholesterol concentration, and cigarette smoking. As compared with men with an optimal level of blood pressure (systolic pressure < 120 mm Hg and diastolic pressure < 80 mm Hg), the relative risk of end-stage renal disease for those with stage 4 hypertension (systolic pressure > or = 210 mm Hg or diastolic pressure > or = 120 mm Hg) was 22.1 (P < 0.001). These relations were not due to end-stage renal disease that occurred soon after screening and, in the 12,866 screened men who entered the MRFIT study, were not changed by taking into account the base-line serum creatinine concentration and urinary protein excretion. The estimated risk of end-stage renal disease associated with elevations of systolic pressure was greater than that linked with elevations of diastolic pressure when both variables were considered together.
CONCLUSIONS: Elevations of blood pressure are a strong independent risk factor for end-stage renal disease; interventions to prevent the disease need to emphasize the prevention and control of both high-normal and high blood pressure.

Entities:  

Mesh:

Year:  1996        PMID: 7494564     DOI: 10.1056/NEJM199601043340103

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  364 in total

Review 1.  Preventing renal disease progression: is it the drug or the blood pressure reduction, or both?

Authors:  M R Weir
Journal:  Curr Hypertens Rep       Date:  2000-12       Impact factor: 5.369

Review 2.  What is the optimal strategy to intensify blood pressure control and prevent progression of renal failure?

Authors:  M Epstein; S Tobe
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

Review 3.  Evidence based management of hypertension. Cardiovascular risk factors and their effects on the decision to treat hypertension: evidence based review.

Authors:  R Padwal; S E Straus; F A McAlister
Journal:  BMJ       Date:  2001-04-21

Review 4.  Renal sympathetic nerve ablation: the new frontier in the treatment of hypertension.

Authors:  Markus P Schlaich; Henry Krum; Paul A Sobotka
Journal:  Curr Hypertens Rep       Date:  2010-02       Impact factor: 5.369

5.  Resistive index predicts renal prognosis in chronic kidney disease: results of a 4-year follow-up.

Authors:  Toshihiro Sugiura; Akira Wada
Journal:  Clin Exp Nephrol       Date:  2010-11-11       Impact factor: 2.801

Review 6.  Epidemiology of hypertensive kidney disease.

Authors:  Suneel Udani; Ivana Lazich; George L Bakris
Journal:  Nat Rev Nephrol       Date:  2010-11-16       Impact factor: 28.314

7.  Kidney disease and antihypertensive medication adherence: the need for improved measurement tools.

Authors:  Tara I Chang; Wolfgang C Winkelmayer
Journal:  Am J Kidney Dis       Date:  2010-09       Impact factor: 8.860

8.  Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans.

Authors:  Barry I Freedman; Pamela J Hicks; Meredith A Bostrom; Mary E Cunningham; Yongmei Liu; Jasmin Divers; Jeffrey B Kopp; Cheryl A Winkler; George W Nelson; Carl D Langefeld; Donald W Bowden
Journal:  Kidney Int       Date:  2009-01-28       Impact factor: 10.612

Review 9.  Antihypertensive drugs and the kidney.

Authors:  Mitra K Nadim; Renee Dua; Vito M Campese
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

Review 10.  Blood pressure control--effects on diabetic nephropathy progression: how low does blood pressure have to be?

Authors:  Christopher A Newton; Philip Raskin
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.